Medical disclaimer: This website is for research and education only. Nothing here is medical advice, diagnosis, treatment, or a recommendation to use any peptide, supplement, or protocol. Always consult a qualified healthcare provider before making health decisions. Read the full disclaimer.
A 2026 review of randomized trials suggests possible muscle-endurance and biomarker effects, but functional benefits remain inconsistent and long-term evidence is limited.
Urolithin A is a metabolite that certain gut microbes can produce from ellagitannins and ellagic acid found in foods such as pomegranates, walnuts, and some berries. Production varies substantially among people because it depends on microbiome composition. Directly administered urolithin A bypasses this variable microbial conversion.
Research has focused on mitophagy, the cellular process that identifies and removes damaged mitochondria. Preclinical experiments suggest urolithin A can influence mitochondrial quality control, inflammation, and muscle function, but mechanisms demonstrated in cells or animals do not establish clinical benefits in humans.
The principal human-focused source supplied for this update is a 2026 review of randomized controlled trials, rather than a single new clinical trial. It evaluated outcomes such as muscle strength, endurance, physical performance, mitochondrial biomarkers, and safety across existing human studies.
Taken together, the trials indicated that urolithin A could affect some muscle-endurance measures and molecular markers associated with mitochondrial or muscle health. Effects on broader clinical outcomes—including walking performance, overall physical function, and consistently measured strength—were less uniform. Small study populations, differing participant profiles, short follow-up periods, and varied outcome tests limit confidence in the overall effect.
The current signal is biologically plausible but not definitive. Improvements have appeared more consistently in selected endurance or fatigue-related measurements than in global mobility outcomes. A positive laboratory marker or isolated muscle test should not be interpreted as proof that urolithin A slows aging or produces durable real-world benefits.
The 2026 Nutrients review places urolithin A among food-derived compounds being investigated against hallmarks of aging. That framing remains exploratory: trials have not established urolithin A as a treatment for aging, sarcopenia, frailty, or mitochondrial disease. Larger studies with standardized endpoints and longer follow-up are needed.
Reviews published or indexed in 2026 discuss a microbiome–mitochondria axis and possible context-dependent roles for urolithin A in aging and cancer. Most disease-specific claims in these areas remain mechanistic, cell-based, or animal-derived. Mitophagy can have different effects depending on tissue, disease stage, and tumor biology, so it should not automatically be characterized as beneficial in every setting.
A 2026 critical review of urolithin A as a possible neuro-nutraceutical emphasized unresolved questions about brain exposure, pharmacology, and translation to Alzheimer's or Parkinson's disease. There is not adequate human clinical evidence that urolithin A prevents or treats either condition.
A 2022 mouse study of urolithin A plus EGCG in an amyloid-beta model was retracted in July 2026. Its findings should not be used as evidence for efficacy, and it did not provide human clinical evidence even before retraction.
Short-term randomized studies generally described the tested interventions as tolerated under their protocols. However, the available trials were not large or long enough to rule out uncommon adverse effects or establish safety during prolonged use. Evidence is also limited for pregnancy, breastfeeding, children, people with major organ disease, and interactions with medicines or other bioactive compounds.
The 2025–2026 literature supports continued investigation of urolithin A, particularly for mitochondrial biology and selected muscle outcomes, but it does not establish an anti-aging therapy or treatment for muscle, neurologic, or cancer-related conditions. This guide is research information only, not medical advice, a diagnosis, or a recommendation to use any compound or dose.
Research and educational information only — not medical advice.